Alpha Antitrypsin Deficiency (AATD)- Market Insights, Epidemiology and Market Forecast-2030

Alpha Antitrypsin Deficiency (AATD)- Market Insights, Epidemiology and Market Forecast-2030

  • April 2020 •
  • 200 pages •
  • Report ID: 5885400 •
  • Format: PDF
‘Alpha Antitrypsin Deficiency (AATD)- Market Insights, Epidemiology and Market Forecast-2030 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of AATD’s in the United States and EU5 (Germany, Spain, Italy, France and United Kingdom).
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Alpha Antitrypsin Deficiency (AATD) from 2017 to 2030 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
Study Period: 2017–2030
Alpha Antitrypsin Deficiency (AATD) - Disease Understanding and Treatment Algorithm
Alpha Antitrypsin Deficiency (AATD) occurs when the body is unable to produce sufficient amounts of AAT protein, exposing the organs to harmful effects of proteolytic enzymes, such as neutrophil elastase. AAT protein, a protein made in the liver, plays an important role in protecting organs of the body such lungs from proteolytic enzymes, but some causes lead the protein to be unable to enter the bloodstream and work as desired, leading to increased risk of lung disease.

The Alpha Antitrypsin Deficiency (AATD) market report gives the thorough understanding of the AATD by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Alpha Antitrypsin Deficiency in the US and Europe.

Alpha Antitrypsin Deficiency Epidemiology
The Alpha Antitrypsin Deficiency (AATD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 6 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent population of AATD, total diagnosed population of AATD, genotype of AATD diagnosed pool and comorbidities associated with AATD) scenario of Alpha Antitrypsin Deficiency (AATD) in the 6MM covering United States and EU5 countries (Germany, Spain, Italy, France and United Kingdom) from 2017–2030.
According to the report, the total number of prevalent cases of Alpha Antitrypsin Deficiency (AATD) in 6 MM was found to be 175,009, in the year 2017.

Alpha Antitrypsin Deficiency Drug Chapters
This segment of the Alpha Antitrypsin Deficiency report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Current treatment for AATD includes both medicinal and surgical therapies. Both of these categories rely on providing symptomatic relief to the subjects based on the level and severity of their conditions. Commonly used therapy for AATD is similar to chronic obstructive pulmonary disease (COPD) and emphysema treatment: abstinence from smoking, long-acting bronchodilators, antibiotics, inhalations of corticosteroids, and long-acting beta-agonists are recommended. However, the application of such solutions does not increase the functional AAT level in serum. The only currently approved and dedicated treatment for AATD is Augmentation therapy. Weekly intravenous supplementation with the AAT protein purified from pooled healthy donors’ plasma that has become available since the end of the 1980s. It is based on the administration of the purified human AAT at a dose of 60? mg/kg per week in order to achieve the protective level of AAT in serum.

Alpha Antitrypsin Deficiency Market Outlook
The Alpha Antitrypsin Deficiency market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to the report, the market of Alpha Antitrypsin Deficiency in 6MM was found to be USD 698 Million in 2017, and is expected to increase during the course of the study period (2017–2030). Among the 6MM, the United States accounts for the largest market size of AATD, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain).

Alpha Antitrypsin Deficiency Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017–2030. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Alpha Antitrypsin Deficiency Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Alpha Antitrypsin Deficiency Report Key Strengths
• 11 Year Forecast
• 6MM Coverage
• Epidemiology Segmentation

• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Alpha Antitrypsin Deficiency Report Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits
• This report will help to develop Business Strategies by understanding the trends shaping and driving Alpha Antitrypsin Deficiency market
• Organize sales and marketing efforts by identifying the best opportunities for Alpha Antitrypsin Deficiency market
• To understand the future market competition in the Alpha Antitrypsin Deficiency market.